Relapse Multiple Myeloma Clinical Trials

29 clinical trials for Relapse Multiple Myeloma across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma — RECRUITING · PHASE1
• DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM — RECRUITING · PHASE1
• A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• Elranatamab in R/R Multiple Myeloma — RECRUITING · PHASE2
• Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma — RECRUITING · NA
• Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE1
• Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma — RECRUITING · PHASE2
• Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone — RECRUITING · PHASE3
• Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma — RECRUITING · PHASE1
• FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) — NOT_YET_RECRUITING · PHASE1
• A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases — COMPLETED
• A Study of MCARH109 and MCARH125 in People With Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1
• Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma — NOT_YET_RECRUITING
• MMRC Horizon One: RRMM (MMRC-099) — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab — ACTIVE_NOT_RECRUITING · PHASE2
• Melflufen for Elderly Patients With Relapsed Myeloma — WITHDRAWN · PHASE2
• Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma — TERMINATED · PHASE2
• Descartes-25 in Relapsed/Refractory Multiple Myeloma — TERMINATED · PHASE1
• Multiple Myeloma Turkish Prospective Patient Registry — OTHER
• A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma — OTHER · PHASE1
• B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma — OTHER · PHASE1
• A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma — WITHDRAWN · PHASE1
• A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma — NOT_YET_RECRUITING · PHASE1
• A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy — NOT_YET_RECRUITING · PHASE1
• INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma — WITHDRAWN · PHASE1
• Carfilzomib in Combination for the Treatment of RR MM — OTHER
• Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma — OTHER · PHASE3
• Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib — COMPLETED · PHASE2

Refine this search